News &amp; Updates

Tezepelumab demonstrates steroid-sparing potential in patients with severe asthma, reducing maintenance oral corticosteroid use while maintaining asthma control, as shown in the phase III SUNRISE study.

Tezepelumab cuts oral corticosteroid use without compromising asthma control

Early CKD screening in CAD patients must include eGFR, UACR: study

A recent study has emphasized the importance of early screening for chronic kidney disease (CKD) among patients with coronary artery disease (CAD). Both estimated glomerular filtration rate (eGFR) and urinary albumin/creatinine ratio (UACR) must be included in the test to provide a complete diagnosis.

Early CKD screening in CAD patients must include eGFR, UACR: study

Rapid response to obesity medications tied to greater weight loss

A post hoc analysis of the SURMOUNT-5 study reveals more tirzepatide-treated individuals with obesity achieving all body weight (BW) reduction thresholds than semaglutide-treated participants, with rapid responders showing a greater magnitude of weight loss.

Rapid response to obesity medications tied to greater weight loss

09 Jun 2026

Healthy low-carb, low-fat diets may lower CHD risk

The healthy versions of low-carbohydrate (LCD) and low-fat diets (LFD) appear to reduce the risk of coronary heart disease (CHD), suggests a study.

Healthy low-carb, low-fat diets may lower CHD risk

Daraxonrasib makes history in one of the deadliest cancers

Daraxonrasib—an oral, potent RAS(ON) multi-selective, tri-complex inhibitor—demonstrates unprecedented survival benefits in individuals with previously treated metastatic pancreatic adenocarcinoma (mPDAC) in the landmark phase III RASolute 302 study.

Daraxonrasib makes history in one of the deadliest cancers

09 Jun 2026

Oral semaglutide provides limited benefit in individuals with early AD

The use of oral semaglutide does not reduce the speed of clinical progression in individuals with early Alzheimer's disease (AD), according to the results to two phase III trials.

Oral semaglutide provides limited benefit in individuals with early AD

First-in-class P-CAB a game-changer in H. pylori eradication

Vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), produces a sustained gastric acid suppression effect that is both more profound and more rapid than that of proton pump inhibitors (PPIs), making it an essential component of first-line (1L) and second-line (2L) therapy for Helicobacter pylori eradication, according to Professor Takashi Kawai of Tokyo Medical University Hospital, Tokyo, Japan.

First-in-class P-CAB a game-changer in H. pylori eradication

Glycaemic control in T2D better with CGM vs self-monitoring

08 Jun 2026 by

In adult patients with type 2 diabetes (T2D) receiving basal insulin alongside other glucose-lowering medications, real-time continuous glucose monitoring (CGM) demonstrates superiority over self-monitoring of blood glucose (SMBG) in terms of optimizing glycaemic control, according to the FreeDM2 study.

Glycaemic control in T2D better with CGM vs self-monitoring

AI and social media has its place in ENT practice. We cannot avoid the advent of technology, but it must be used with caution.

08 Jun 2026 by

The rapid rise of artificial intelligence (AI) and social media is transforming the face of modern medicine, including how doctors communicate, record consultations, educate patients and build professional reputations. At the recent panel session Scroll, Post, Heal: Smart Social-Media Strategies and AI in Modern ENT, speakers debated the opportunities and threats presented by these fast-evolving technologies.

AI and social media has its place in ENT practice. We cannot avoid the advent of technology, but it must be used with caution.

Are doctors in white coat more trustworthy?

Patient trust does not depend on what doctors wear, according to a study.

Are doctors in white coat more trustworthy?